Examples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries

Authors
Guglielmetti, L
Hewison, C
Avaliani, Z
Hughes, J
Kiria, N
Lomtadze, N
Ndjeka, N
Setkina, S
Shabangu, A
Sikhondze, W
Skrahina, A
Veziris, N
Furin, J
Issue Date
2017-02-01
Submitted date
2017-02-27

Metadata
Show full item record
Journal
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
Abstract
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.
Publisher
International Union Against Tuberculosis and Lung Disease
URI
http://hdl.handle.net/10144/618813
DOI
10.5588/ijtld.16.0493
PubMed ID
28234080
Additional Links
https://www.ncbi.nlm.nih.gov/pubmed/28234080
Language
en
Description
Abstract available only, full article is not open access. To access this article click on "additional links".
ISSN
1815-7920
Collections
TB